- Home
- ALC vs LVS Comparison
ALC vs LVS Comparison
Compare ALC & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALC
- LVS
- Stock Information
- Founded
- ALC 1945
- LVS 1988
- Country
- ALC Switzerland
- LVS United States
- Employees
- ALC N/A
- LVS N/A
- Industry
- ALC Ophthalmic Goods
- LVS Hotels/Resorts
- Sector
- ALC Health Care
- LVS Consumer Discretionary
- Exchange
- ALC Nasdaq
- LVS Nasdaq
- Market Cap
- ALC 40.2B
- LVS 39.5B
- IPO Year
- ALC N/A
- LVS 2004
- Fundamental
- Price
- ALC $75.49
- LVS $58.65
- Analyst Decision
- ALC Buy
- LVS Buy
- Analyst Count
- ALC 11
- LVS 13
- Target Price
- ALC $91.41
- LVS $64.00
- AVG Volume (30 Days)
- ALC 2.3M
- LVS 6.2M
- Earning Date
- ALC 11-11-2025
- LVS 10-22-2025
- Dividend Yield
- ALC 0.28%
- LVS 1.68%
- EPS Growth
- ALC N/A
- LVS 9.73
- EPS
- ALC 2.16
- LVS 2.22
- Revenue
- ALC $10,025,000,000.00
- LVS $12,264,000,000.00
- Revenue This Year
- ALC $5.94
- LVS $9.22
- Revenue Next Year
- ALC $7.71
- LVS $4.97
- P/E Ratio
- ALC $35.02
- LVS $26.83
- Revenue Growth
- ALC 4.04
- LVS 8.37
- 52 Week Low
- ALC $71.55
- LVS $30.18
- 52 Week High
- ALC $99.20
- LVS $59.66
- Technical
- Relative Strength Index (RSI)
- ALC 46.77
- LVS 66.13
- Support Level
- ALC $71.55
- LVS $49.20
- Resistance Level
- ALC $77.01
- LVS $59.66
- Average True Range (ATR)
- ALC 1.09
- LVS 1.87
- MACD
- ALC 0.40
- LVS 1.17
- Stochastic Oscillator
- ALC 72.16
- LVS 92.84
About ALC Alcon Inc.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, the company generates all its EBITDA from Asia, with its casino operations generating the majority of sales.